Last Friday, RegenoCell Therapeutics, Inc. (OTC:RCLL) jumped up 21% on the market and its trading volume increased 
significantly. However, the gain was not taken by chance. On the contrary, the reasons for it are crystal clear – positive news and promotions.
The news came up right on Friday, when RegenoCell reported that it was planning to open another state of the art facility in Panama for patients to be treated for congestive heart failure and peripheral artery disease with the company’s autologous stem cell therapy.
Though, it looks like RCLL did not consider the good news enough to strengthen its market position, thus the stock re-ensured it by promotions. The campaign started yesterday and it continues today, meaning that there is a great possibility for RCLL continue climbing. Especially, when the promotional alerts are shouting that RegenoCell could save millions of lives by its cell therapy.
Yet, what is more interesting is that the company obviously pays for the alerts by itself, as no third party was related to the campaign, which cost $80.000 by now.[BANNER]
It seems that RCLL controls the situation at this point, however, there is another issue the company should deal with. Its last 10-Q report does not look promising at all.
As of 31 March, this year total liabilities of RCLL are eight times higher than its total assets, while the stockholders’ deficiency is over $4 million, almost as much as the company’s accumulated deficit is. At the same time, RCLL has other losses incurred and its revenues are not sufficient to cover them.
Having in mind these results, apparently, RegenoCell will continue to operate under a going concern status until the company finds a better way to get profitable.
